The review covers adults with a BMI over 30, or 27 to 30 with a weight-related condition. Prof Michael Barry says funding it may need a wider shift in health policy.
Recap by typeshit. Full story at Irish Medical Times.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
A JAMA Network Surgery study found GLP-1 prescriptions up 24% since 2018. A Tulane surgeon says in Louisiana, surgery is more often covered than the drugs.
STAT
STAT, citing the AP, notes the peptides involved aren't FDA approved as safe or effective and most of their data comes from animal studies.
Loading…